A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome

Trial Profile

A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2017

At a glance

  • Drugs TOP 1630 (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors TopiVert
  • Most Recent Events

    • 05 Jul 2017 Status changed from recruiting to completed.
    • 16 Mar 2017 Status changed to recruiting.
    • 28 Nov 2016 According to a TopiVert media release, an Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top